SI9500200A - Insulin analog formulations. - Google Patents

Insulin analog formulations. Download PDF

Info

Publication number
SI9500200A
SI9500200A SI9500200A SI9500200A SI9500200A SI 9500200 A SI9500200 A SI 9500200A SI 9500200 A SI9500200 A SI 9500200A SI 9500200 A SI9500200 A SI 9500200A SI 9500200 A SI9500200 A SI 9500200A
Authority
SI
Slovenia
Prior art keywords
insulin
human
complex
pro
lys
Prior art date
Application number
SI9500200A
Other languages
English (en)
Slovenian (sl)
Inventor
L Diane Bakaysa
N David Brems
H Bruce Frank
A Henry Havel
H Allen Pekar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9500200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI9500200A publication Critical patent/SI9500200A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
SI9500200A 1994-06-16 1995-06-14 Insulin analog formulations. SI9500200A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (1)

Publication Number Publication Date
SI9500200A true SI9500200A (en) 1996-02-29

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9500200A SI9500200A (en) 1994-06-16 1995-06-14 Insulin analog formulations.

Country Status (39)

Country Link
US (1) US5474978A (cs)
JP (2) JP3171541B2 (cs)
KR (1) KR100382326B1 (cs)
CN (1) CN1105576C (cs)
AT (1) AT408720B (cs)
BE (1) BE1009408A5 (cs)
BR (1) BR9502795A (cs)
CA (1) CA2151560C (cs)
CH (2) CH689250A5 (cs)
CO (1) CO4410203A1 (cs)
CZ (1) CZ287484B6 (cs)
DE (1) DE19521720B4 (cs)
DK (1) DK173015B1 (cs)
ES (1) ES2091727B1 (cs)
FI (1) FI118207B (cs)
FR (2) FR2721214B1 (cs)
GB (1) GB2291427B (cs)
GR (1) GR1003004B (cs)
HK (1) HK1015138A1 (cs)
HU (1) HU227240B1 (cs)
IE (1) IE68853B1 (cs)
IL (1) IL114151A (cs)
IT (1) IT1276723B1 (cs)
LU (1) LU88626A1 (cs)
MY (1) MY115631A (cs)
NL (1) NL1000566C2 (cs)
NO (1) NO322128B1 (cs)
NZ (1) NZ272359A (cs)
PE (1) PE19496A1 (cs)
PL (1) PL181310B1 (cs)
PT (1) PT101722B (cs)
RO (1) RO113530B1 (cs)
RS (1) RS49577B (cs)
RU (1) RU2152399C2 (cs)
SE (1) SE509052C2 (cs)
SI (1) SI9500200A (cs)
TW (1) TW421596B (cs)
UA (1) UA26874C2 (cs)
ZA (1) ZA954943B (cs)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
CA2258097C (en) * 1996-06-20 2011-02-08 Novo Nordisk A/S Insulin preparations containing nacl
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
IL134901A0 (en) 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69901726T2 (de) * 1998-10-16 2002-12-19 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
BR9914568A (pt) * 1998-10-16 2001-07-03 Novo Nordisk As Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
EP1131089B1 (en) * 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1383540B1 (en) * 2000-07-31 2009-04-29 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
ES2412306T3 (es) 2002-01-09 2013-07-11 Emisphere Technologies, Inc. Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
JP4864701B2 (ja) 2003-06-17 2012-02-01 セムバイオシス ジェネティクス インコーポレイテッド 植物におけるインスリンの製造方法
DE602004021603D1 (de) * 2003-07-25 2009-07-30 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
AU2005240213B8 (en) 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
JP4995080B2 (ja) * 2004-05-14 2012-08-08 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するためのアリールケトン化合物および組成物
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
EP1773376A4 (en) 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
ES2544329T3 (es) * 2004-10-05 2015-08-28 Novo Nordisk A/S Una formulación farmacéutica que contiene insulina cristalina e insulina disuelta
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1862174A1 (en) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Inhibitor for insulin polymer formation
EP1940440A4 (en) 2005-08-29 2009-11-11 Healor Ltd METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN
JP2009508875A (ja) * 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090069216A1 (en) * 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP2134351B1 (en) 2007-03-13 2016-04-27 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2008116141A1 (en) * 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
EP2514412A1 (en) * 2007-04-30 2012-10-24 Novo Nordisk A/S Highly Concentrated Insulin Solutions and Compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
PT2215047E (pt) 2007-11-02 2014-01-20 Emisphere Tech Inc Processo para o tratamento da deficiência de vitamina b12
JP5780958B2 (ja) 2008-07-31 2015-09-16 ケイス、ウエスタン、リザーブ、ユニバーシティ ハロゲン安定化インスリン
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
MA33064B1 (fr) 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
ES2493618T3 (es) 2009-02-12 2014-09-12 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
RU2012133148A (ru) 2010-01-11 2014-02-20 Хилор Лтд. Способ лечения воспалительного заболевания и расстройства
AU2011220867B2 (en) * 2010-02-24 2014-05-15 Emisphere Technologies, Inc. Oral B12 therapy
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
EP2621911A1 (en) 2010-09-30 2013-08-07 Solvay Sa Derivative of epichlorohydrin of natural origin
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
WO2014015078A1 (en) 2012-07-17 2014-01-23 Michael Weiss O-linked carbohydrate-modified insulin analogues
EP3332810B1 (fr) 2012-11-13 2021-01-13 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6111475B2 (ja) 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
MX2015006997A (es) 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
WO2018222787A1 (en) 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
KR20220115927A (ko) 2019-10-25 2022-08-19 세르카코르 래버러토리즈, 인크. 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법
KR20220161422A (ko) 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
EP0705275B1 (en) * 1993-06-21 1999-02-03 Novo Nordisk A/S Asp-b28 insulin crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
AU694501B2 (en) 1998-07-23
IT1276723B1 (it) 1997-11-03
CZ154295A3 (en) 1996-02-14
NO952357D0 (no) 1995-06-14
JP2001199899A (ja) 2001-07-24
FI952931A0 (fi) 1995-06-14
FR2721214A1 (fr) 1995-12-22
FR2741078A1 (fr) 1997-05-16
RO113530B1 (ro) 1998-08-28
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
KR960000924A (ko) 1996-01-25
NL1000566C2 (nl) 1996-12-03
PT101722B (pt) 1997-02-28
PL181310B1 (pl) 2001-07-31
NZ272359A (en) 1996-10-28
DK67795A (da) 1995-12-17
LU88626A1 (fr) 1996-02-01
ES2091727A1 (es) 1996-11-01
CN1122248A (zh) 1996-05-15
ZA954943B (en) 1997-09-14
HU227240B1 (en) 2010-12-28
UA26874C2 (uk) 1999-12-29
FR2721214B1 (fr) 1997-09-26
PL309098A1 (en) 1995-12-27
RU2152399C2 (ru) 2000-07-10
PT101722A (pt) 1995-12-29
GR950100229A (en) 1996-02-29
FI952931A (fi) 1995-12-17
BR9502795A (pt) 1996-03-12
AU2168095A (en) 1996-01-04
SE9502167L (sv) 1995-12-17
ITMI951278A1 (it) 1996-12-14
CH689250A5 (de) 1999-01-15
NL1000566A1 (nl) 1995-12-18
SE9502167D0 (sv) 1995-06-14
FI118207B (fi) 2007-08-31
AT408720B (de) 2002-02-25
FR2741078B1 (fr) 1998-08-07
PE19496A1 (es) 1996-06-01
ITMI951278A0 (it) 1995-06-14
GB2291427B (en) 1998-09-16
CN1105576C (zh) 2003-04-16
IE68853B1 (en) 1996-07-24
IL114151A (en) 2000-09-28
NO322128B1 (no) 2006-08-21
CH689935A5 (de) 2000-02-15
YU39695A (sh) 1997-08-22
KR100382326B1 (ko) 2003-07-07
ATA101695A (de) 2001-07-15
BE1009408A5 (fr) 1997-03-04
CA2151560A1 (en) 1995-12-17
DE19521720A1 (de) 1995-12-21
TW421596B (en) 2001-02-11
HUT73186A (en) 1996-06-28
CO4410203A1 (es) 1997-01-09
IL114151A0 (en) 1995-10-31
IE950436A1 (en) 1995-12-27
HK1015138A1 (en) 1999-10-08
DE19521720B4 (de) 2009-09-03
RU95110109A (ru) 1997-05-10
GR1003004B (el) 1998-11-05
HU9501716D0 (en) 1995-08-28
CZ287484B6 (en) 2000-12-13
SE509052C2 (sv) 1998-11-30
GB9512038D0 (en) 1995-08-09
MY115631A (en) 2003-08-30
DK173015B1 (da) 1999-11-15
CA2151560C (en) 2000-05-09
NO952357L (no) 1995-12-18
JPH083067A (ja) 1996-01-09
JP3171541B2 (ja) 2001-05-28
US5474978A (en) 1995-12-12
RS49577B (sr) 2007-04-10

Similar Documents

Publication Publication Date Title
SI9500200A (en) Insulin analog formulations.
US5547929A (en) Insulin analog formulations
AU734781B2 (en) Stable insulin formulations
KR100386038B1 (ko) 단량체성인슐린유사체의제제
JP5832439B2 (ja) Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
US6174856B1 (en) Stabilized insulin compositions
EP0921812B1 (en) Insulin preparations containing a halogenide
EP3618840B1 (en) Stable insulin formulations
EP1283051B1 (en) Stable insulin formulations
AU731636B2 (en) Insulin analog formulations

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20051019